Evolution of recombinant lymphocytic choriomeningitis virus/Lassa virus in vivo highlights the importance of the GPC cytosolic tail in viral fitness

Journal of Virology

Volumn 88, Issue 15, 2014, Pages 8340-8348

  Sommerstein, Rami ^a   da Palma, Joel Ramos ^b   Ölschläger, Stephan ^b   Bergthaler, Andreas ^a   Barba, Leticia ^b   Lee, Boris P L ^a   Pasquato, Antonella ^b   Flatz, Lukas ^b,c  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c Institute of Immunobiology   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ENVELOPE GLYCOPROTEIN PRECURSOR; GLYCOPROTEIN; GLYCOPROTEIN 2; PROTEIN PRECURSOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOSYNTHESIS; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOSOL; CYTOSOLIC TAIL; EMBRYO; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LASSA VIRUS; LOSS OF FUNCTION MUTATION; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; VIRAL CLEARANCE; VIREMIA; VIRUS EXPRESSION; VIRUS TITRATION; VIRUS VIRULENCE;

ANIMALS; ANTIGENS, VIRAL; EVOLUTION, MOLECULAR; GLYCOPROTEINS; HUMANS; LASSA VIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MICE; MICE, INBRED C57BL; MUTANT PROTEINS; POINT MUTATION; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; RECOMBINATION, GENETIC; VIRAL LOAD; VIRAL PROTEINS; VIREMIA;

EID: 84903907712     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00236-14     Document Type: Article

References (43)

1. Zinkernagel RM. 2002. Lymphocytic choriomeningitis virus and immunology. Curr. Top. Microbiol. Immunol. 263:1-5.
2. Ahmed R, Hahn CS, Somasundaram T, Villarete L, Matloubian M, Strauss JH. 1991. Molecular basis of organ-specific selection of viral variants during chronic infection. J. Virol. 65:4242-4247.
3. Bergthaler A, Flatz L, Hegazy AN, Johnson S, Horvath E, Lohning M, Pinschewer DD. 2010. Viral replicative capacity is the primary determinant of lymphocytic choriomeningitis virus persistence and immunosuppression. Proc. Natl. Acad. Sci. U.S.A. 107:21641-21646. http://dx.doi.org/10.1073/pnas.1011998107.
4. Oldstone MB, Campbell KP. 2011. Decoding arenavirus pathogenesis: essential roles for alpha-dystroglycan-virus interactions and the immune response. Virology 411:170-179. http://dx.doi.org/10.1016/j.virol.2010.11.023.
5. Sevilla N, Kunz S, Holz A, Lewicki H, Homann D, Yamada H, Campbell KP, de La Torre JC, Oldstone MB. 2000. Immunosuppression and resultant viral persistence by specific viral targeting of dendritic cells. J. Exp. Med. 192:1249-1260. http://dx.doi.org/10.1084/jem.192.9.1249.
6. Capul AA, Perez M, Burke E, Kunz S, Buchmeier MJ, de la Torre JC. 2007. Arenavirus Z-glycoprotein association requires Z myristoylation but not functional RING or late domains. J. Virol. 81:9451-9460. http://dx.doi.org/10.1128/JVI.00499-07.
7. Bowen MD, Rollin PE, Ksiazek TG, Hustad HL, Bausch DG, Demby AH, Bajani MD, Peters CJ, Nichol ST. 2000. Genetic diversity among Lassa virus strains. J. Virol. 74:6992-7004. http://dx.doi.org/10.1128/JVI.74.15.6992-7004.2000.
8. Gunther S, Lenz O. 2004. Lassa virus. Crit. Rev. Clin. Lab Sci. 41:339-390. http://dx.doi.org/10.1080/10408360490497456.
9. Haas WH, Breuer T, Pfaff G, Schmitz H, Kohler P, Asper M, Emmerich P, Drosten C, Golnitz U, Fleischer K, Gunther S. 2003. Imported Lassa fever in Germany: surveillance and management of contact persons. Clin. Infect. Dis. 36:1254-1258. http://dx.doi.org/10.1086/374853.
10. Kitching A, Addiman S, Cathcart S, Bischop L, Krahe D, Nicholas M, Coakley J, Lloyd G, Brooks T, Morgan D, Turbitt D. 2009. A fatal case of Lassa fever in London, January 2009. Euro Surveill. 14(6):pii:19117. http://www.eurosurveillance.org/viewarticle.aspx?ArticleId=19117.
11. Olschlager S, Flatz L. 2013. Vaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trials. PLoS Pathog. 9:e1003212. http://dx.doi.org/10.1371/journal.ppat.1003212.
12. Burri DJ, Pasquato A, da Palma JR, Igonet S, Oldstone MB, Kunz S. 2013. The role of proteolytic processing and the stable signal peptide in expression of the Old World arenavirus envelope glycoprotein ectodomain. Virology 436:127-133. http://dx.doi.org/10.1016/j.virol.2012.10.038.
13. Capul AA, de la Torre JC, Buchmeier MJ. 2011. Conserved residues in Lassa fever virus Z protein modulate viral infectivity at the level of the ribonucleoprotein. J. Virol. 85:3172-3178. http://dx.doi.org/10.1128/JVI.02081-10.
14. Albarino CG, Bird BH, Chakrabarti AK, Dodd KA, White DM, Bergeron E, Shrivastava-Ranjan P, Nichol ST. 2011. Reverse genetics generation of chimeric infectious Junin/Lassa virus is dependent on interaction of homologous glycoprotein stable signal peptide and G2 cytoplasmic domains. J. Virol. 85:112-122. http://dx.doi.org/10.1128/JVI.01837-10.
15. Bergthaler A, Gerber NU, Merkler D, Horvath E, de la Torre JC, Pinschewer DD. 2006. Envelope exchange for the generation of liveattenuated arenavirus vaccines. PLoS Pathog. 2:e51. http://dx.doi.org/10.1371/journal.ppat.0020051.
16. Lukashevich IS, Patterson J, Carrion R, Moshkoff D, Ticer A, Zapata J, Brasky K, Geiger R, Hubbard GB, Bryant J, Salvato MS. 2005. A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J. Virol. 79:13934-13942. http://dx.doi.org/10.1128/JVI.79.22.13934-13942.2005.
17. Pinschewer DD, Perez M, Sanchez AB, de la Torre JC. 2003. Recombinant lymphocytic choriomeningitis virus expressing vesicular stomatitis virus glycoprotein. Proc. Natl. Acad. Sci. U.S.A. 100:7895-7900. http://dx.doi.org/10.1073/pnas.1332709100.
18. Pasqual G, Rojek JM, Masin M, Chatton JY, Kunz S. 2011. Old world arenaviruses enter the host cell via the multivesicular body and depend on the endosomal sorting complex required for transport. PLoS Pathog. 7:e1002232. http://dx.doi.org/10.1371/journal.ppat.1002232.
19. Rojek JM, Sanchez AB, Nguyen NT, de la Torre JC, Kunz S. 2008. Different mechanisms of cell entry by human-pathogenic Old World and New World arenaviruses. J. Virol. 82:7677-7687. http://dx.doi.org/10.1128/JVI.00560-08.
20. Lee AM, Cruite J, Welch MJ, Sullivan B, Oldstone MB. 2013. Pathogenesis of Lassa fever virus infection. I. Susceptibility of mice to recombinant Lassa Gp/LCMV chimeric virus. Virology 442:114-121. http://dx.doi.org/10.1016/j.virol.2013.04.010.
21. Flatz L, Bergthaler A, de la Torre JC, Pinschewer DD. 2006. Recovery of an arenavirus entirely from RNA polymerase I/II-driven cDNA. Proc. Natl. Acad. Sci. U.S.A. 103:4663-4668. http://dx.doi.org/10.1073/pnas.0600652103.
22. Flatz L, Hegazy AN, Bergthaler A, Verschoor A, Claus C, Fernandez M, Gattinoni L, Johnson S, Kreppel F, Kochanek S, Broek M, Radbruch A, Levy F, Lambert PH, Siegrist CA, Restifo NP, Lohning M, Ochsenbein AF, Nabel GJ, Pinschewer DD. 2010. Development of replicationdefective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. Nat. Med. 16:339-345. http://dx.doi.org/10.1038/nm.2104.
23. Battegay M, Cooper S, Althage A, Banziger J, Hengartner H, Zinkernagel RM. 1991. Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24-or 96-well plates. J. Virol. Methods 33:191-198. http://dx.doi.org/10.1016/0166-0934(91)90018-U.
24. Flatz L, Rieger T, Merkler D, Bergthaler A, Regen T, Schedensack M, Bestmann L, Verschoor A, Kreutzfeldt M, Bruck W, Hanisch UK, Gunther S, Pinschewer DD. 2010.Tcell-dependence of Lassa fever pathogenesis. PLoS Pathog. 6:e1000836. http://dx.doi.org/10.1371/journal.ppat.1000836.
25. Rawson RB, DeBose-Boyd R, Goldstein JL, Brown MS. 1999. Failure to cleave sterol regulatory element-binding proteins (SREBPs) causes cholesterol auxotrophy in Chinese hamster ovary cells with genetic absence of SREBP cleavage-activating protein. J. Biol. Chem. 274:28549-28556. http://dx.doi.org/10.1074/jbc.274.40.28549.
26. Buchmeier MJ, Lewicki HA, Tomori O, Oldstone MB. 1981. Monoclonal antibodies to lymphocytic choriomeningitis and pichinde viruses: generation, characterization, and cross-reactivity with other arenaviruses. Virology 113:73-85. http://dx.doi.org/10.1016/0042-6822(81)90137-9.
27. Kunz S, Edelmann KH, de la Torre JC, Gorney R, Oldstone MB. 2003. Mechanisms for lymphocytic choriomeningitis virus glycoprotein cleavage, transport, and incorporation into virions. Virology 314:168-178. http://dx.doi.org/10.1016/S0042-6822(03)00421-5.
28. Domingo E, Sheldon J, Perales C. 2012. Viral quasispecies evolution. Microbiol. Mol. Biol. Rev. 76:159-216. http://dx.doi.org/10.1128/MMBR.05023-11.
29. Eichler R, Lenz O, Strecker T, Eickmann M, Klenk HD, Garten W. 2003. Identification of Lassa virus glycoprotein signal peptide as a transacting maturation factor. EMBO Rep. 4:1084-1088. http://dx.doi.org/10.1038/sj.embor.7400002.
30. Lenz O, ter Meulen J, Klenk HD, Seidah NG, Garten W. 2001. The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. Proc. Natl. Acad. Sci. U.S.A. 98:12701-12705. http://dx.doi.org/10.1073/pnas.221447598.
31. Rojek JM, Pasqual G, Sanchez AB, Nguyen NT, de la Torre JC, Kunz S. 2010. Targeting the proteolytic processing of the viral glycoprotein precursor is a promising novel antiviral strategy against arenaviruses. J. Virol. 84:573-584. http://dx.doi.org/10.1128/JVI.01697-09.
32. Schlie K, Strecker T, Garten W. 2010. Maturation cleavage within the ectodomain of Lassa virus glycoprotein relies on stabilization by the cytoplasmic tail. FEBS Lett. 584:4379-4382. http://dx.doi.org/10.1016/j.febslet.2010.09.032.
33. Dalton AJ, Rowe WP, Smith GH, Wilsnack RE, Pugh WE. 1968. Morphological and cytochemical studies on lymphocytic choriomeningitis virus. J. Virol. 2:1465-1478.
34. Murphy FA, Webb PA, Johnson KM, Whitfield SG, Chappell WA. 1970. Arenoviruses in Vero cells: ultrastructural studies. J. Virol. 6:507-518.
35. Kunz S, Sevilla N, Rojek JM, Oldstone MB. 2004. Use of alternative receptors different than alpha-dystroglycan by selected isolates of lymphocytic choriomeningitis virus. Virology 325:432-445. http://dx.doi.org/10.1016/j.virol.2004.05.009.
36. Radoshitzky SR, Kuhn JH, Spiropoulou CF, Albarino CG, Nguyen DP, Salazar-Bravo J, Dorfman T, Lee AS, Wang E, Ross SR, Choe H, Farzan M. 2008. Receptor determinants of zoonotic transmission of New World hemorrhagic fever arenaviruses. Proc. Natl. Acad. Sci. U.S.A. 105:2664-2669. http://dx.doi.org/10.1073/pnas.0709254105.
37. Salvato M, Borrow P, Shimomaye E, Oldstone MB. 1991. Molecular basis of viral persistence: a single amino acid change in the glycoprotein of lymphocytic choriomeningitis virus is associated with suppression of the antiviral cytotoxic T-lymphocyte response and establishment of persistence. J. Virol. 65:1863-1869.
38. Albarino CG, Bird BH, Chakrabarti AK, Dodd KA, Flint M, Bergeron E, White DM, Nichol ST. 2011. The major determinant of attenuation in mice of the Candid1 vaccine for Argentine hemorrhagic fever is located in the G2 glycoprotein transmembrane domain. J. Virol. 85:10404-10408. http://dx.doi.org/10.1128/JVI.00856-11.
39. Igonet S, Vaney MC, Vonhrein C, Bricogne G, Stura EA, Hengartner H, Eschli B, Rey FA. 2011. X-ray structure of the arenavirus glycoprotein GP2 in its postfusion hairpin conformation. Proc. Natl. Acad. Sci. U.S.A. 108:19967-19972. http://dx.doi.org/10.1073/pnas.1108910108.
40. Klewitz C, Klenk HD, ter Meulen J. 2007. Amino acids from both N-terminal hydrophobic regions of the Lassa virus envelope glycoprotein GP-2 are critical for pH-dependent membrane fusion and infectivity. J. Gen. Virol. 88:2320-2328. http://dx.doi.org/10.1099/vir.0.82950-0.
41. York J, Nunberg JH. 2007. A novel zinc-binding domain is essential for formation of the functional Junin virus envelope glycoprotein complex. J. Virol. 81:13385-13391. http://dx.doi.org/10.1128/JVI.01785-07.
42. Albarino CG, Ghiringhelli PD, Posik DM, Lozano ME, Ambrosio AM, Sanchez A, Romanowski V. 1997. Molecular characterization of attenuated Junin virus strains. J. Gen. Virol. 78(Part 7):1605-1610.
43. Maiztegui JI, McKee KT, Jr, Barrera Oro JG, Harrison LH, Gibbs PH, Feuillade MR, Enria DA, Briggiler AM, Levis SC, Ambrosio AM, Halsey NA, Peters CJ. 1998. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group. J. Infect. Dis. 177:277-283. http://dx.doi.org/10.1086/514211.